Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)

Background The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis. Among these, risankizumab, an anti-IL-23, was shown to be effective both in clinical tri...

Full description

Saved in:
Bibliographic Details
Main Authors: Diego Orsini, Chiara Assorgi, Claudio Bonifati, Norma Cameli, Dario Graceffa, Luca Potestio, Matteo Megna
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2358150
Tags: Add Tag
No Tags, Be the first to tag this record!